Search hospitals > Missouri > Saint Louis

Siteman Cancer Center at Christian Hospital

Claim this profile
Saint Louis, Missouri 63110
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
491 reported clinical trials
69 medical researchers
Photo of Siteman Cancer Center at Christian Hospital in Saint LouisPhoto of Siteman Cancer Center at Christian Hospital in Saint LouisPhoto of Siteman Cancer Center at Christian Hospital in Saint Louis

Summary

Siteman Cancer Center at Christian Hospital is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Lymphoma, Pancreatic Cancer and other specialties. Siteman Cancer Center at Christian Hospital is involved with conducting 491 clinical trials across 609 conditions. There are 69 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and Premal H Thaker, M.D., M.S..

Area of expertise

1Lung Cancer
Global Leader
Siteman Cancer Center at Christian Hospital has run 103 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Siteman Cancer Center at Christian Hospital has run 89 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Siteman Cancer Center at Christian Hospital

Lung Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Breast cancer
Small Cell Lung Cancer
Brain Tumor
Esophageal cancer
Cancer
Colorectal Cancer
Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Proton Craniospinal Radiation

for Cancer in the Brain and Spinal Cord

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Siteman Cancer Center at Christian Hospital?
Where is Siteman Cancer Center at Christian Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Siteman Cancer Center at Christian Hospital accept?
What awards or recognition has Siteman Cancer Center at Christian Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security